The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 7 rounds in the feed, most often at Series C and in Biotech.
A pioneering investment management firm that uses machine learning to evaluate individual companies as long-term investments
Venture capitaleuclidean.comRounds from 2021-06-16 to 2026-10-30
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Setara Biosciences A clinical-stage rare disease biotech formed by Actio Biosciences alums | Series A Verified against 4 of 45 sources | $90M | 2026-10-30 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series E Verified against 5 sources | $92.5M |
| 2026-09-16 |
| [ PART ] |
Savvy Wealth Savvywealth provides a wealth management platform that offers services and technology to independent financial advisors. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-09-09 | [ PART ] |
Savvy Wealth Savvywealth provides a wealth management platform that offers services and technology to independent financial advisors. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $72M | 2025-07-02 | [ PART ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Funding round Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $102M | 2025-04-03 | [ PART ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Seed Developing, 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2024-02-08 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2021-06-16 | [ PART ] |